Nordic Bioscience is participating in EASL NAFLD 2022
"NAFLD is the leading cause of chronic liver disease, along with higher risk of diabetes, cardiovascular disease, and cancer, and thus a major public health challenge. NAFLD represents a therapeutic area of as yet unmet clinical lead.
This 4th iteration of the EASL NAFLD Summit promises to bring together all of you engaged in tackling NAFLD, including clinicians, researchers, policy and public health specialists, and industry professionals." (EASL NAFLD 2022)
Nordic Bioscience is looking forward to participating in this key hepatology event where we will discuss our latest NAFLD data and advancements in the field. In the meantime, feel free to browse our biomarker panels for hepatic diseases.
